Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00691665 · ClinicalTrials.gov registry record · Phase 4

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

A Phase 4 study of Seasonal Allergic Rhinitis, sponsored by Alcon Research.

Completed
Registry status
Phase 4
Development phase
130
Enrollment target
1
Study location

NCT00691665 is a Phase 4 study of Seasonal Allergic Rhinitis that has completed, run by Alcon Research. The registered enrollment target is 130 participants, below the 660-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00691665, a Phase 4 study of Seasonal Allergic Rhinitis, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 4
Development phase
130 participants
Enrollment target
1
Study location

Study Summary

Comparison of two nasal sprays for the treatment of seasonal allergic rhinitis

Conditions Studied

Interventions

  • DRUG Olopatadine HCL Nasal Spray, 0.6%
  • DRUG Fluticasone Propionate Nasal Spray, 50 mcg

Study Locations (1)

California

  • Sacramento, CA - Sacramento

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2008-05
Phase Phase 4

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT00691665

The ClinicalTrials.gov registry entry for NCT00691665 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 660-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (80% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Olopatadine HCL Nasal Spray, 0.6% is the first listed.

NCT00691665 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00691665 about?

NCT00691665 is a clinical study titled "Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial". Comparison of two nasal sprays for the treatment of seasonal allergic rhinitis

What is the current status of trial NCT00691665?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2008-05.

What conditions does trial NCT00691665 study?

This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.

What interventions are being tested in trial NCT00691665?

The interventions under investigation include: Olopatadine HCL Nasal Spray, 0.6% (DRUG), Fluticasone Propionate Nasal Spray, 50 mcg (DRUG).

Who is sponsoring clinical trial NCT00691665?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00691665 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seasonal Allergic Rhinitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.